<DOC>
	<DOCNO>NCT00474006</DOCNO>
	<brief_summary>Determine effect escalate dose daunorubicin induction treatment adult patient acute myelogenous leukemia young 60 year age .</brief_summary>
	<brief_title>High Dose Daunorubicin Vs. Standard Dose Daunorubicin Induction Treatment AML</brief_title>
	<detailed_description>1 . Induction chemotherapy - For patient randomized receive regular dose Daunorubicin ( Arm I ) give Cytarabine 200 mg/m2/day continuous iv infusion 24 hour daily 7 day along Daunorubicin 45 mg/m2/day continuous iv infusion 24 hour daily 3 day . - For patient randomize receive high dose Daunorubicin ( Arm II ) give Cytarabine 200 mg/m2/day continuous iv infusion 24 hour daily 7 day along Daunorubicin 90 mg/m2/day continuous iv infusion 24 hour daily 3 day . 2 . Reinduction chemotherapy - Bone marrow aspiration biopsy perform day 14 induction chemotherapy . If bone marrow hypoplastic contain 5 % blast cell , chemotherapy defer marrow examination repeat time ANC ≥ 1,500/μl platelet ≥ 100,000/μl peripheral blood evaluation complete remission . If 5 % blast cell persist marrow cellularity biopsy specimen exceed 15 % , course reinduction chemotherapy give . - Reinduction chemotherapy consist Cytarabine 200 mg/m2/day continuous iv infusion 24 hour daily 5 day along Daunorubicin 45 mg/m2/day continuous iv infusion 24 hour daily 2 day arm . 3 . Postremission therapy - The postremission therapy give patient arm . - Four course Cytarabine 3 g/m2 administer 3-hour iv infusion every 12 hour ( twice daily ) day 1 , 3 , 5 total six dos per course . After four course Cytarabine therapy , patient receive two monthly treatment Cytarabine ( 200 mg/m2/day 3-hour iv infusion 5 day ) Daunorubicin ( 45 mg/m2 rapid iv infusion first treatment day ) . - If patient HLA-matched sibling unrelated donor , allogeneic stem cell transplantation perform . - A complete remission define ≤ 5 % blast normocellular bone marrow ANC ≥ 1,500/μl platelet ≥ 100,000/μl peripheral blood disappearance blast bone marrow .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients newly diagnose AML RAEB 15 year age old , young 60 year age Adequate hepatic renal function Normal cardiac function LVEF ≥ 50 % MUGA scan echocardiogram Written inform consent promyelocytic leukemia chronic myelogenous leukemia significant infection prior chemotherapy history leukemia</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>